Metformin-Akrikhin

Akrikhin JSC is one of the leading Russian pharmaceutical companies, producing effective, affordable and high-quality medicines from the therapeutic groups most in demand by Russian patients.

The company is one of the top five leading local pharmaceutical manufacturers in the Russian pharmaceutical market in terms of sales volume, while showing significant growth and development rates.

AKRIKHIN is focused on constantly updating its product portfolio through its own developments, as well as through effective cooperation with other pharmaceutical companies and leading research institutes in Russia and other countries.

The company's product portfolio includes about 200 drugs, more than a hundred of which are produced at a production site in the Moscow region. Our drugs belong to the main pharmacotherapeutic areas - tuberculosis, diabetes, dermatology, cardiology, neurology, gynecology, etc. and are produced in full compliance with GMP standards. 45% of drugs in the sales volume of products manufactured by the company are included in the list of vital and essential drugs.

Fully complying with government and industry priorities, AKRIKHIN JSC is actively involved in the localization and import substitution of medicines both through its own Research and Development Center and in partnership with international pharmaceutical manufacturers. During 2014-2015 As part of the import substitution program, the company released 10 drugs.

The AKRIKHIN production complex is located 20 km from Moscow and includes workshops for the production of hard and soft dosage forms, the production volume of which in recent years has been about 100 million packages. Between 2011 and 2022. the company implemented an investment program, which resulted in the modernization and development of the production complex. The total volume of investments during this period amounted to about 3.2 billion rubles.

It employs 1,500 employees, of which more than 800 are at the production site in Staraya Kupavna (Moscow region). In 2017, the company took fourth place in the annual HeadHunter list “Rating of Russian Employers - 2017” in the “Pharmaceuticals and Medicine” category, and also entered the top 100 best employers in Russia. In addition, AKRIKHIN has become one of the leading companies with the most highly developed HR processes.

It also took 3rd position in the “Rating of the Influence of Subjects of the Russian Pharmaceutical Market” in the TOP 10 Russian drug manufacturers that had the greatest impact on the pharmaceutical market in 2022.

Persons

Alexandra Lukashova

Vice President of Marketing and Sales of Branded and Generic Drugs

Alexey Maltsev

Vice President of OTC Sales and Marketing

Konstantin Paramonov

Vice President of Operations

Irina Redzyuk

Vice President of Regulatory Affairs and New Developments

Olga Smaznaya

Commercial Director

Olga Stepanova

Director of the Center for Scientific Research and Development (CNIiR)

Olga Frolikova

Director of OTC Marketing

Denis Chetverikov

The president

Faiza Yagudina

Director of quality

Akrikhin industrial complex

The AKRIKHIN production site is a modern complex on an area of 36 hectares, 20 km from Moscow, in the city of Staraya Kupavna.

The production complex includes:

2 workshops for the production of finished medicinal products:

solid finished dosage forms, soft dosage forms;

Quality Control Center;
Research and Development Center;
Warehouses for finished products, customs, raw materials.

The company's production workshops are equipped with modern equipment from leading suppliers: IMA, GLATT, CAM, IKA, BOSCH, etc.

The production complex and the qualified AKRIKHIN personnel employed in it ensure the rapid and reliable implementation of the most modern technological processes and the latest technologies.

Between 2011 and 2016

AKRIKHIN implemented a large-scale program for the modernization and development of the production complex with a total investment of more than 35 million euros. The result of the program was:

expansion and rational placement of all production capacities in two enlarged workshops;
bringing all main and auxiliary premises into strict compliance with international GMP standards;
replacement of more than 30% of the equipment in production workshops with new high-tech samples;
full automation of the processes of packaging and packing of finished products;
reduction of time production costs by more than a quarter.

Quality control

Compliance with international GMP standards at all stages of development, production and storage of medicines is a guarantee of the effectiveness and safety of medicines produced by AKRIKHIN.

AKRIKHIN is the first Russian pharmaceutical company to receive a GMP certificate from the authorized body of the German government in 1999 for the industrial production of cardiovascular drugs together with the Bristol-Myers Squibb Corporation.

In 2003, based on the results of the World Health Organization (WHO) inspection of the anti-tuberculosis drug program, a conclusion was issued on the compliance of the quality assurance system with WHO GMP requirements.

AKRIKHIN regularly undergoes quality audits conducted by the company’s foreign partners in contract and licensed production, Russian and foreign certification bodies, and regulatory authorities.

In total, from 2000 to 2016. the company has successfully passed the quality assurance system audit MORE than 30 times

In 2015, AKRIKHIN received a GMP certificate from the Ministry of Industry and Trade of the Russian Federation.

Audits conducted by foreign partners make it possible to introduce modern GMP practices and international experience, thereby ensuring improved quality of manufactured drugs. Positive audit results, adherence to international GMP standards, and high professionalism of employees make AKRIKHIN an attractive partner in the field of contract manufacturing for such well-known foreign pharmaceutical corporations as Merck Sharp and Dohme (MSD), Bristol-Myers Squibb (BMS), Johnson & Johnson (J&J).

As part of the investment program for development and modernization, in 2015 AKRIKHIN completed bringing the entire production complex into compliance with the requirements of GMP quality standards.

The quality control of manufactured drugs is carried out by the quality control center. On average, per year, this division tests more than 1,600 series of raw materials, 3,000 series of packaging materials, and produces about 4,500 series of finished products with quality certificates issued and assigned the appropriate status in the operating ERP system.

News

08.12.2021

The Akrikhina production complex received an official delegation from Kyrgyzstan

Pharmaceutical manufacturer shared practical experience in implementing a labeling system
Production

03.12.2021

Akrikhin raises awareness of visual diseases

In the coming years, the manufacturer plans to introduce several new products to the market.
Production

12.11.2021

Akrikhin announced the expansion of the AquaDetrim product line

In the near future, soluble tablets in a dosage of 2000 IU will go on sale.
Production

All publications

AKRIKHIN

Contacts

Address: 142450, Russia, Moscow region, Noginsky district, Staraya Kupavna, st. Kirova, 29 Tel./fax, 702-95-03 E-mail Official website: https://www.akrikhin.ru

About the company

The company was founded in 1936.

JSC Chemical and Pharmaceutical Plant AKRIKHIN (JSC AKRIKHIN) is one of the leading Russian pharmaceutical companies producing affordable, effective and high-quality medicines. The company is among the top 5 largest local pharmaceutical manufacturers in terms of sales and production volume on the Russian pharmaceutical market.

JSC AKRIKHIN produces a wide range of socially significant drugs, making its contribution to the development of the Russian healthcare system. The company is one of the largest Russian manufacturers of drugs included in the List of Vital and Essential Medicines (VED), as well as drugs for the treatment of tuberculosis and diabetes.

The production complex of AKRIKHIN JSC is located 20 km from Moscow. The company's production includes workshops for the production of medicines of almost all forms: tablets, capsules, liniments, ointments, creams, syrups, gels, suppositories, etc. The company's annual production volume is more than 60 million packages. Medicines are produced on foreign equipment from high-quality raw materials based on the latest technologies. The modern warehouse complex of the enterprise has more than 4.5 thousand pallet spaces, ensuring proper storage of medicines.

Manufactured products

The company produces more than 150 drugs of various dosage forms: tablets, capsules, ointments, suppositories, creams, syrups. AKRIKHIN concentrates on therapeutic areas of high social significance, i.e. most in demand by the Russian healthcare system: cardiology, diabetes mellitus, neurology, dermatology, tuberculosis, gynecology, pediatrics.

History of the enterprise

1936 Foundation of the company. The first industrial batch of the drug Akrikhin for the treatment of malaria was released, which gave the name to the enterprise and made it possible to quickly eliminate such a dangerous disease as malaria.

1950-1990. The enterprise was one of the main production facilities of pharmaceutical substances in the Soviet Union, providing 24% of the volume of substances produced in the country.

1992 The enterprise was transformed into an open joint stock company. A decision was made to repurpose the enterprise’s work from the chemical synthesis of substances to the production of finished medicines.

2007 Beginning of a strategic partnership with the Polish pharmaceutical company Polpharma. The partnership involves close cooperation between companies in the development, production, promotion and distribution of medicines.

Links:

Official website of JSC "AKRIKHIN"

Lactic acidosis

Lactic acidosis is a very rare but serious (high mortality unless promptly treated) complication that can occur due to accumulation of metformin. Cases of lactic acidosis when taking metformin occurred mainly in patients with diabetes mellitus with severe renal failure.

Other associated risk factors should be taken into account, such as decompensated diabetes mellitus, ketosis, prolonged fasting, alcoholism, severe infectious disease, liver failure and any condition associated with severe hypoxia, and concomitant use of drugs that can cause the development of lactic acidosis (see See section “Interactions with other drugs”), which may help reduce the incidence of lactic acidosis.

The risk of developing lactic acidosis should be taken into account when nonspecific signs appear, such as muscle cramps accompanied by dyspeptic disorders, abdominal pain and severe asthenia.

Lactic acidosis is characterized by acidotic shortness of breath, abdominal pain and hypothermia followed by coma. Diagnostic laboratory parameters are a decrease in blood pH (less than 7.35), lactate content in the blood plasma over 5 mmol/l, increased anion gap and lactate/pyruvate ratio.

If lactic acidosis is suspected, stop taking the drug and consult a doctor immediately.

Surgical operations

The use of metformin should be discontinued 48 hours before elective surgery and can be continued no earlier than 48 hours after, provided that renal function has been found to be normal during the examination.

Kidney function

Since metformin is excreted by the kidneys, before starting treatment and regularly thereafter, it is necessary to determine CC: at least once a year in patients with normal renal function, every 3-6 months in patients with normal creatinine clearance 45-59 ml/min and every 3 months in patients with CC 30-44 ml/min.

In the case of CC less than 30 ml/min, the use of the drug is contraindicated. Particular caution should be exercised in case of possible impairment of renal function in elderly patients, with dehydration (chronic or severe diarrhea, repeated bouts of vomiting), and with the simultaneous use of antihypertensive drugs, diuretics or non-steroidal anti-inflammatory drugs.

Heart failure

Patients with heart failure have a higher risk of developing hypoxia and renal failure. In patients with chronic heart failure, cardiac and renal function should be regularly monitored while taking metformin.

In acute heart failure and in chronic heart failure with unstable hemodynamic parameters, the use of metformin is contraindicated.

Children and teenagers

The diagnosis of type 2 diabetes mellitus must be confirmed before starting treatment with metformin.

In clinical studies lasting 1 year, metformin was shown to have no effect on growth and puberty. However, due to the lack of long-term data, careful monitoring of the subsequent effects of metformin on these parameters in children, especially during puberty, is recommended.

Clinical experience with metformin in children aged 10 to 12 years is limited, so the most careful monitoring is necessary in children in this age group.

Use of iodine-containing radiocontrast agents:

Intravascular administration of iodine-containing radiocontrast agents can lead to the development of renal failure and accumulation of metformin, which increases the risk of developing lactic acidosis. Metformin should be discontinued depending on renal function, 48 hours before or during an X-ray examination using iodinated contrast agents, and not resumed until 48 hours after it, provided that during the examination, renal function was found to be normal.

Other precautions:

Patients are advised to continue to follow a diet with even carbohydrate intake throughout the day. Overweight patients are advised to continue to follow a low-calorie diet (but not less than 1000 kcal/day).

It is recommended that routine laboratory tests be performed regularly to monitor diabetes mellitus.

Metformin does not cause hypoglycemia when used alone, but caution is recommended when used in combination with insulin or other hypoglycemic agents (for example, sulfonylureas or repaglinide).

The use of metformin in patients with prediabetes is recommended in the presence of additional risk factors for the development of overt type 2 diabetes mellitus, which include:

age less than 60 years;
body mass index (BMI) ≥30 kg/m2;
history of gestational diabetes mellitus;
family history of diabetes mellitus in first-degree relatives;
increased concentration of triglycerides;
reduced concentration of HDL cholesterol;
arterial hypertension. Metformin did not affect fertility in male or female rats when administered at doses three times the maximum recommended daily dose for humans.